Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Cetuximab, an epidermal growth factor receptor inhibitor, is a safe therapeutic alternative for advanced or unresectable cutaneous squamous cell carcinoma (cSCC).1 To our knowledge, this is the first case to describe an inflammatory cutaneous reaction with accentuation of lesions after cessation of cetuximab therapy.
A man in his 50s presented with numerous hyperkeratotic erythematous papules and plaques on his face and scalp. He had undergone heart transplantation 2 years earlier and was since taking sirolimus and tacrolimus. After the transplant, he was hospitalized for disseminated aspergillosis necessitating the use of voriconazole.
Giambrone D, Correa-Selm LM, Firoz BF. An Inflammatory Skin Reaction After Cetuximab Treatment for Aggressive Cutaneous Squamous Cell Carcinoma in a Heart Transplant Patient Previously Taking Voriconazole. JAMA Dermatol. Published online December 23, 2015. doi:10.1001/jamadermatol.2015.4529